PUBLIC INDUSTRY INTELLIGENCE

Industry updates · Page 7

Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.

Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗

npj Computational Materials

Normalizing flows support molecular-crystal free-energy ranking across three pharmaceutical-relevant systems

A study in npj Computational Materials combines normalizing flows with targeted Bennett acceptance ratio calculations to estimate molecular-crystal lattice free energies. Validation on succinic acid, veliparib, and mivebresib agreed closely with the Einstein crystal method while reducing computational cost. The approach addresses anharmonic free-energy ranking rather than relying only on static lattice energies.

BioAgilytix

BioAgilytix opens a 360biolabs laboratory in Sydney

BioAgilytix announced a new 360biolabs laboratory in Sydney's Macquarie Park district. The company describes support for time-sensitive clinical samples, PBMC isolation, flow cytometry, and sample storage. It says shared procedures and quality systems support assay transfer across its laboratory network. These are company-reported capabilities.

Journal of controlled release : official journal of the Controlled Release Society

Uncovering the lymphatic uptake, pharmacokinetics, and biodistribution of mRNA-lipid nanoparticles after intravenous and subcutaneous injection

Using three established ionizable lipids, researchers measured RNA, lipid components, lymphatic transport, plasma exposure, and tissue reporter expression in rats. After subcutaneous injection, lymph concentrations exceeded plasma concentrations, but lipid and RNA trafficking did not fully match. The study demonstrates why tracking a lipid label alone may not accurately represent intact RNA delivery or productive expression in tissues.

Nature Reviews Materials

Programmable mRNA vaccine materials for temporal control of antitumour immunity

A Perspective proposes designing mRNA vaccine materials around changing immune conditions before and after cancer surgery. The framework considers a broadly applicable preoperative prime followed by a personalized postoperative boost, with carriers controlling expression and immune activation. It is a conceptual design roadmap, not evidence from a new clinical trial.

npj Drug Discovery

MAGEA11 recruitment enables selective BET degradation in cancer cell models

Researchers developed BET-targeting PROTACs that recruit the tissue-restricted scaffolding protein MAGEA11 rather than relying on widely expressed ligases. Lead compound 105B degraded BET proteins in two cancer cell lines but not in HEK293T cells. Mechanistic experiments implicated MAGEA11 and HUWE1. The authors emphasized that further optimization is needed to produce selective cytotoxicity.

MEPSGEN US / PR Newswire

MEPSGEN launches small-volume NanoCalibur Mini nanoparticle formulation system

MEPSGEN has launched NanoCalibur Mini for automated formulation of lipid and polymeric nanoparticles at volumes of 0.1 to 3 milliliters. The system targets early screening when payloads and excipients are scarce. The company says its platforms retain identical microfluidic mixing geometry across scales and increase throughput through parallelization, an approach intended to reduce process redevelopment during technology transfer.

WuXi AppTec

WuXi AppTec reports nine-month 2026 results and raises full-year guidance

WuXi AppTec reported nine-month 2026 revenue of RMB 45.54 billion, up 38.6% year over year. Revenue from continuing operations rose 46.3%, and continuing-operations backlog reached RMB 76.74 billion, up 36.4%. The company also raised full-year guidance. Total-revenue and continuing-operations growth rates use different reporting scopes and should not be treated as interchangeable.

Moderna

INTerpath-001 details Phase 3 benefit of personalized mRNA therapy in melanoma

Moderna reported detailed results from the randomized, double-blind Phase 3 INTerpath-001 trial in completely resected stage IIB–IV melanoma. Adding intismeran autogene to pembrolizumab improved recurrence-free survival in the prespecified intention-to-treat analysis: hazard ratio 0.58 (95% CI 0.45–0.75), with 24.6 months median follow-up. Grade 3–5 treatment-related adverse events occurred in 14.2% versus 13.4%. The treatment remains investigational.

Crystal Growth & Design (ACS)

Vitamin B6 ternary eutectics change solubility and permeability in two BCS IV drugs

Researchers combined pyridoxine hydrochloride with mesalamine or acetazolamide and p-aminobenzoic acid to prepare ternary eutectic solids. The systems altered pH-dependent solubility and membrane permeability. Characterization distinguished a physical mixture from a cocrystal-containing eutectic, emphasizing that multicomponent formulations can have different phase identities. The reported laboratory results do not establish human bioavailability improvements.

Crystal Growth & Design (ACS)

Ivacaftor study links milling-induced solvates to starting form and crystal surfaces

A study of ivacaftor examined how solvent identity, liquid-additive volume, milling time, and starting solid form affect mechanochemical solvate formation. Crystalline Form C and amorphous material followed different transformation patterns. Structural and surface analyses suggest that mechanically exposed polar groups contribute to solvent incorporation, rather than solvent class or apparent dissolution capacity alone explaining the outcome.

Molecular therapy : the journal of the American Society of Gene Therapy

A Scalable, Antibody-Free Lipid Nanoparticle Achieves Preferential mRNA Delivery to Human HSPCs In Vivo Without Conditioning

A ligand-free nanoparticle formulation preferentially delivered mRNA to human hematopoietic stem and progenitor cells in humanized mice without conditioning. It reduced hepatic delivery relative to an SM-102 comparator and enabled functional Cas9-mediated editing of human CD34-positive cells. Single-cell analyses supported tolerability under the conditions examined. Durable stem-cell function and clinical delivery still require further investigation.

Crystal Growth & Design (ACS)

Supramolecular gel supports furosemide salt-cocrystal growth at lower concentration

Researchers developed a calix[4]arene-based supramolecular gel whose assembly is triggered by dihydrogen phosphate. A salt cocrystal containing furosemide and its tetrabutylammonium salt grew within the gel at a lower furosemide concentration than required in the corresponding solution. The work demonstrates a crystallization environment, rather than a clinically validated pharmaceutical formulation or a ready-to-use manufacturing process.

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗
AI assistant ↗